Significantly improved PFS has been observed in BRAF-mutant melanomas when BRAF and MEK inhibitors are used in combination (Larkin et al, 2014; Long et al, 2014); median PFS of 9.9 months was reported from a study of vemurafenib+cobimetinib, and PFS of 9.3 months was reported from a study of dabrafenib+trametinib. This evidence concerns the gene MAP2K7 and melanoma.